Comparative assessment of the efficacy of onabotulinumtoxinA and oral therapies (anticholinergics and mirabegron) for overactive bladder: a systematic review and network meta-analysis.
Marcus J DrakeVictor W NittiDavid A GinsbergBenjamin M BruckerZsolt HeppRachael McCoolJulie M GlanvilleKelly J FleetwoodDaniel JamesChristopher R ChapplePublished in: BJU international (2017)
The results indicate that, after 12 weeks, onabotulinumtoxinA 100 U provides greater relief of OAB symptoms compared with most other licensed doses of other pharmacotherapies in the network.